Merck/DOV Triple Reuptake Inhibitor Phase II For Depression Planned In 2006
This article was originally published in Pharmaceutical Approvals Monthly
Merck and DOV continue to expect to have the first triple reuptake inhibitor for depression on the market despite a revised licensing pact that returns initial clinical trial responsibility for DOV's 21,947 compound to DOV
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class